Tweenvest Stocks

Kohjin Bio Co., Ltd. (TSE: 177A)

Health Care · Biotechnology · JP

¥875.00

-0.57% today · -47.6% 1Y

Kohjin Bio Co., Ltd. (TSE: 177A) operates in the Biotechnology industry within the Health Care sector. The company is valued at $28.11M and employs 176 people.

Over the last twelve months the share price has lost 47.6%, trading between 841.00 and 2.02K.

Tweenvest scores Kohjin Bio Co., Ltd. across four factors: quality 67/100, value 64/100, dividend 31/100. Its strongest factor is quality.

177A price history

Not enough price history to draw a chart yet.

Key figures

Market cap
$28.11M
Revenue (TTM)
$31.06M
P/E
17.82
EPS
49.10
Dividend yield
1.14%
Beta (5Y)
0.00
52-week high
¥2,020.00
52-week low
¥841.00
Avg volume (3M)
Shares outstanding
5.11M
Employees
176
Next earnings

About Kohjin Bio Co., Ltd.

Kohjin Bio Co., Ltd., established in 1981 in Sakado, Japan, and known as Kohjin Co.,Ltd. until its rebranding in 1989, is a diversified life science enterprise. The company's core business involves the production and sale of various biological materials, including animal blood, sera, cell culture media, agar media for microbial assays, in-vitro diagnostic products, and cosmetics. Its extensive catalog for cell and tissue culture features specialized mediums crucial for virus and recombinant protein synthesis, hybridoma development, human lymphocyte cultivation, and insect cell lines. Additionally, Kohjin Bio supplies complementary items such as gas-permeable cell culture bags, cryopreservation agents, medium supplements, normal human cells along with their growth media, ES cell media, and comprehensive kits for in-vitro fertilization and early embryo culture. The firm further provides essential laboratory tools like cell separation solutions, physiological salt solutions, and a range of research reagents. Within microbiology, Kohjin Bio offers a wide array of culture media tailored for various applications. For clinical diagnostics, this includes mediums for identifying gram-positive cocci and gram-negative bacteria, susceptibility testing, general differentiation, anaerobic growth, and fungal detection, alongside tube mediums for confirmatory tests and expansion. For food safety, their products cover sterilization assessments, and the detection of E. coli, coliform bacteria, Staphylococcus spp., Bacillus cereus, and Vibrio parahaemolyticus. The company also produces mediums for total viable cell count determination and specific media for Campylobacter and fungi. The company's blood and serum division offers normal human blood, serum, and plasma, as well as pathological human serum. Its animal blood portfolio encompasses preserved, defibrinated, and hemolyzed animal blood, in addition to animal serum and plasma, with custom-designed formulations like Eagle medium also available. Beyond its manufacturing activities, Kohjin Bio engages in the breeding and distribution of laboratory animals, the sale of medical equipment, and provides contract services for animal immunization and antibody preparation. The company also manages the import and export of its diverse products and raw materials internationally.

ISIN
JP3283630006
Founded
1981
Listed since
Apr 25, 2024
Exchange
The Tokyo Stock Exchange
Currency
JPY
CompanyMarket capPriceDay
AbbVie Inc.NYSE: ABBV$467.44B$264.41-0.04%
Amgen Inc.NasdaqGS: AMGN$239.95B$445.03+0.27%
Gilead Sciences, Inc.NasdaqGS: GILD$181.95B$146.74+0.42%
Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX$138.79B$547.59-0.08%
Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN$82.73B$828.50-0.66%
argenx SEENXTBR: ARGX$63.06B874.40+1.18%
CSL LimitedASX: CSL$57.94BAU$169.11+0.48%
Moderna, Inc.NasdaqGS: MRNA$55.45B$141.54+1.91%

Browse every Biotechnology company →

Figures last refreshed Aug 18, 2026.